Synergy CRO

Belkins
Since 2002, SRG provides support to the pharmaceutical, biotechnology and medical device industries with a comprehensive range of collaborative services and solutions. In order to help our clients meet their clinical research goals we constantly explore and implement new ways to evolve the drug development process as well as look for cost-effective solutions. Through this work, we have come to value and respect up to date technologies along with time-tested traditional solutions. Loyalty to traditions, Openness to innovation With its unique philosophic mindset, Synergy is now the leading full-service contract research organization (CRO).

Related News

PHARMA TECH

TETRATE-NAMED-2021-COOL-VENDOR-IN-CLOUD-COMPUTING-BY-GARTNER

Omnicell | November 11, 2021

news image

Omnicell, Inc. a leading provider of medication management solutions and adherence tools for health systems and pharmacies, and Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition, are collaborating to provide U.S. hospitals and health systems with innovative new pharmacy technology designed to support safety and efficiency in dispensing of controlled substances in patient care areas. Managin...

Read More

CHINA TURNS ROCHE ARTHRITIS DRUG ACTEMRA AGAINST COVID-19 IN NEW TREATMENT GUIDELINES

FiercePharma | March 04, 2020

news image

Some patients infected with the novel coronavirus can develop uncontrolled immune response, leading to potentially life-threatening damage to lung tissue. After seeing promising results in clinical practice, Chinese authorities now recommend a Roche arthritis drug to tackle that rampage. Roche’s blockbuster Actemra, first approved by the U.S. FDA in 2010 for rheumatoid arthritis, can now be used to treat serious coronavirus patients with lung damage, China’s National Health Commissio...

Read More

RESEARCH

DEBIOPHARM INVESTS IN VERISIM LIFE'S $15M SERIES A ROUND TO ADVANCE AI-ENABLED DRUG RESEARCH

Debiopharm International SA | January 11, 2022

news image

Debiopharm a Swiss biopharmaceutical company, announced their co-investment in California-based start-up VeriSIM Life's $15 Million Series A Round to advance their mission to accelerate drug development via technology powered by artificial intelligence. VeriSIM Life's computational platform reduces time and cost of drug development as well as reduces the need for animal testing that, in the vast majority of cases, does not translate well to humans. Debiopharm's co-investment in VeriS...

Read More

GILEAD LAUNCHES TWO PHASE III TRIALS OF REMDESIVIR FOR COVID-19

BioSpace: | February 27, 2020

news image

Gilead Sciences, based in Foster City, California, announced it will launch two Phase III clinical trials of its investigational antiviral drug remdesivir in adults diagnosed with COVID-19, the disease caused by the novel coronavirus. The outbreak began in China in December and has since spread through much of the rest of the world, with most cases concentrated in Asia. The current number of confirmed cases worldwide is greater than 81,400 with a total death count of 2,770. The first cases of co...

Read More
news image

PHARMA TECH

TETRATE-NAMED-2021-COOL-VENDOR-IN-CLOUD-COMPUTING-BY-GARTNER

Omnicell | November 11, 2021

Omnicell, Inc. a leading provider of medication management solutions and adherence tools for health systems and pharmacies, and Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition, are collaborating to provide U.S. hospitals and health systems with innovative new pharmacy technology designed to support safety and efficiency in dispensing of controlled substances in patient care areas. Managin...

Read More
news image

CHINA TURNS ROCHE ARTHRITIS DRUG ACTEMRA AGAINST COVID-19 IN NEW TREATMENT GUIDELINES

FiercePharma | March 04, 2020

Some patients infected with the novel coronavirus can develop uncontrolled immune response, leading to potentially life-threatening damage to lung tissue. After seeing promising results in clinical practice, Chinese authorities now recommend a Roche arthritis drug to tackle that rampage. Roche’s blockbuster Actemra, first approved by the U.S. FDA in 2010 for rheumatoid arthritis, can now be used to treat serious coronavirus patients with lung damage, China’s National Health Commissio...

Read More
news image

RESEARCH

DEBIOPHARM INVESTS IN VERISIM LIFE'S $15M SERIES A ROUND TO ADVANCE AI-ENABLED DRUG RESEARCH

Debiopharm International SA | January 11, 2022

Debiopharm a Swiss biopharmaceutical company, announced their co-investment in California-based start-up VeriSIM Life's $15 Million Series A Round to advance their mission to accelerate drug development via technology powered by artificial intelligence. VeriSIM Life's computational platform reduces time and cost of drug development as well as reduces the need for animal testing that, in the vast majority of cases, does not translate well to humans. Debiopharm's co-investment in VeriS...

Read More
news image

GILEAD LAUNCHES TWO PHASE III TRIALS OF REMDESIVIR FOR COVID-19

BioSpace: | February 27, 2020

Gilead Sciences, based in Foster City, California, announced it will launch two Phase III clinical trials of its investigational antiviral drug remdesivir in adults diagnosed with COVID-19, the disease caused by the novel coronavirus. The outbreak began in China in December and has since spread through much of the rest of the world, with most cases concentrated in Asia. The current number of confirmed cases worldwide is greater than 81,400 with a total death count of 2,770. The first cases of co...

Read More